Latest / Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Tirzepatide vs Semaglutide for Obesity, Understanding SURMOUNT-5
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Full results from the SURMOUNT-5 trial show tirzepatide (Zepbound) led to significantly greater weight loss than semaglutide 2.4 mg (Wegovy) in adults with obesity, according to findings published in The New England Journal of Medicine and presented at the 32nd European Congress on Obesity.“The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management,” said…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.